. 2016 Apr;22(4):10.18553/jmcp.2016.22.4.326. doi: 10.18553/jmcp.2016.22.4.326

TABLE 1.

Baseline Demographic, Clinical, and Gout Characteristics Pre- and Post-Propensity Matching

	Pre-match						Post-match
	Allopurinol (n = 3,534)		Febuxostat (n = 1,613)		P Value	Std Diff	Allopurinol (n = 1,486)		Febuxostat (n = 1,486)		P Value	Std Diff
Demographics
Mean [SD] age, years	68.5	[12.8]	67.4	[12.7]	< 0.001	8.2	67.3	[12.9]	67.5	[12.6]	0.665	−1.6
Male (n, %)	2,195	62.1	1,055	65.4	0.037	−6.9	962	64.7	958	64.5	0.878	0.6
Comorbidities (n, %)
CVD, any	2,951	83.5	1,337	82.9	0.929	1.6	1,231	82.8	1,233	83.0	0.922	−0.4
Cerebrovascular	329	9.3	119	7.4	0.022	7.0	109	7.3	111	7.5	0.889	−0.5
Dysrhythmias	835	23.6	383	23.7	0.963	−0.3	344	23.1	351	23.6	0.762	−1.1
Heart failure	817	23.1	333	20.6	0.067	6.0	313	21.1	308	20.7	0.822	0.8
Hypertension	2,517	71.2	1,111	68.9	0.890	5.1	1,044	70.3	1,032	69.4	0.632	1.8
IH D/athero sclero si s	1,035	29.3	462	28.6	0.336	1.4	400	26.9	437	29.4	0.131	−5.5
Peripheral vascular	314	8.9	138	8.6	0.845	1.2	114	7.7	129	8.7	0.315	−3.7
Chronic liver	24	0.7	23	1.4	0.013	−7.3	15	1.0	17	1.1	0.722	−1.3
COPD	446	12.6	166	10.3	0.011	7.3	155	10.4	158	10.6	0.858	−0.7
CKD stage 3^a	2,646	74.9	1,203	74.6	0.810	0.7	1,112	74.8	1,106	74.4	0.800	0.9
CKD stage 4^a	709	20.1	342	21.2	0.719	−2.8	317	21.3	318	21.4	0.964	−0.2
Diabetes mellitus	1,483	42.0	673	41.7	0.735	0.5	627	42.2	624	42.0	0.911	0.4
Dyslipidemia	1,124	31.8	448	27.8	0.124	8.8	412	27.7	417	28.1	0.838	−0.8
Renal failure	763	21.6	356	22.1	0.741	−1.2	324	21.8	323	21.7	0.965	0.2
Gout measures (n, %)
Presence of tophi	75	2.1	92	5.7	< 0.001	−18.5	61	4.1	52	3.5	0.388	3.2
Patients ≥ 1 gout attack	1,774	50.2	975	60.4	< 0.001	−20.7	879	59.2	873	58.7	0.823	0.8
Mean [SD] attacks	0.6	[0.8]	0.9	[1.0]	< 0.001	−31.5	0.8	[0.9]	0.8	[0.9]	0.510	−2.4
First-line ULT	3,409	96.5	799	49.5	< 0.001	124.5	1,424	95.8	743	50.0	<0.001	120.4
Second-line ULT	125	3.5	814	50.5	< 0.001	−124.5	62	4.2	743	50.0	<0.001	−120.4
Colchicine	1,359	38.5	852	52.8	< 0.001	−29.1	760	51.1	762	51.3	0.942	−0.3
Glucocorticoids	2,037	57.6	1,109	68.8	< 0.001	−23.2	994	66.9	996	67.0	0.938	−0.3
NSAIDs	1,209	34.2	563	34.9	0.601	−1.5	501	33.7	510	34.3	0.728	−1.3
Probenecid	52	1.5	41	2.5	0.009	−7.6	33	2.2	30	2.0	0.702	1.4
Other medications (n, %)
Antihyperlipidemics	2,428	68.7	1,098	68.1	0.513	1.4	1,025	69.0	1,013	68.2	0.635	1.7
ACE inhibitors	1,563	44.2	638	39.6	0.002	9.5	589	39.6	595	40.0	0.822	−0.8
ARBs	1,245	35.2	669	41.5	< 0.001	−12.9	589	39.6	609	41.0	0.455	−2.7
Antibiotics	2,285	64.7	1,098	68.1	0.047	−7.2	1,001	67.4	1,007	67.8	0.814	−0.9
Antidiabetic agents	1,381	39.1	655	40.6	0.542	−3.1	605	40.7	610	41.0	0.852	−0.7
Antihyperlipidemics	2,428	68.7	1,098	68.1	0.513	1.4	1,025	69.0	1,013	68.2	0.635	1.7
Opiate analgesics	2,122	60.0	1,028	63.7	0.044	−7.6	954	64.2	935	62.9	0.469	2.7
Mean [SD] CCI	3.9	[1.9]	3.8	[1.9]	0.401	2.6	3.8	[1.8]	3.8	[1.9]	0.929	−0.3
Mean [SD] cost ($)	1,666	[2,300]	1,785	[2,408]	0.261	−5.1	1,749	[2,724]	1,751	[2,309]	0.982	−0.1

^a CKD stage based on the stage reported nearest the study index date.

ACE inhibitor = angiotensin-converting enzyme inhibitor; ARB = angiotensin II receptor blocker; CCI = Charlson Comorbidity Index; CKD = chronic kidney disease;

COPD = chronic obstructive pulmonary disease; CVD = cardiovascular disease; IHD = ischemic heart disease; NSAID = nonsteroidal anti-inflammatory drug; SD = standard deviation; Std Diff = standard difference; ULT = urate-lowering therapy